CHRS
Coherus BioSciences Inc
1.30$
-3.1%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 80.3% | 74.5% | 70.0% | 78.0% | 72.7% | 91.6% | 91.2% | 88.7% | 79.3% | 75.5% | 76.2% | 80.0% | |
| 80.3% | 74.5% | 70.0% | 78.0% | 72.7% | 43.4% | 64.3% | 61.4% | 13.2% | 16.3% | 28.1% | 34.4% | |
| 80.3% | 74.5% | 70.0% | 78.0% | 72.7% | 43.4% | 64.3% | 61.4% | 39.9% | 18.7% | 28.1% | 66.6% | |
| 2.3% | 0.7% | 1.0% | – | -1.8% | 34.7% | 18.7% | 18.1% | 22.9% | 41.4% | 27.3% | 7.1% | |
| -4.4% | -2.1% | -2.7% | 0.0% | 1.7% | 13.5% | 5.3% | 5.5% | 8.1% | 9.9% | 15.6% | 1.2% | |
| 2.4% | 4.9% | 6.0% | 7.9% | 6.7% | 4.0% | 5.7% | 9.3% | 17.7% | – | – | – | |
| 0.5% | 0.4% | 0.5% | 0.6% | 0.9% | 0.2% | 0.1% | 0.1% | 0.2% | 0.1% | 0.0% | – | |
| 1.4% | 1.2% | 1.5% | 1.6% | 2.6% | 0.6% | 0.3% | 0.4% | 1.0% | 11.2% | 12.0% | 17.9% | |
| 64.3% | 103.3% | 89.2% | 81.2% | 138.8% | 74.3% | 66.6% | 85.6% | 128.6% | 130.7% | 129.4% | 76.4% | |
| 27.7% | 49.9% | 31.6% | 17.5% | 33.4% | 28.1% | 17.3% | 24.3% | 28.8% | 52.7% | 63.1% | 54.9% | |
| 6.0% | 11.4% | 0.5% | 0.1% | – | 0.5% | 0.4% | 0.5% | 0.9% | 0.3% | 0.4% | 0.7% | |
| 5.8% | 13.9% | 11.5% | 9.7% | 15.4% | 6.4% | 1.8% | 2.4% | 2.4% | 5.6% | 6.3% | 3.8% | |
| 0.0% | 0.0% | 56.2% | 62.5% | 103.6% | 43.6% | 44.8% | 60.1% | 46.9% | 75.2% | 59.1% | 14.3% | |
| 35.7% | -3.3% | 10.8% | 18.8% | -38.8% | 25.7% | 33.4% | 14.4% | -28.6% | -30.7% | -29.4% | 23.6% | |
| -99.7% | -193.0% | -301.0% | -476.9% | -990.1% | -218.9% | -90.6% | -154.5% | -279.0% | -250.9% | -345.8% | -535.3% | |
| 4.4% | 17.5% | 23.5% | 32.7% | 65.4% | 17.9% | 9.9% | 11.1% | 16.1% | 15.0% | 25.6% | 46.6% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.